Antibody Drug Conjugate Market Size Estimated to Reach $3,356.1 Million by 2025

Antibody Drug Conjugate Market size is estimated to reach $3,356.1 Million by 2025, growing at a CAGR of 14.1% during the forecast period 2020-2025. Antibody drug conjugates or ADCs are the bio-pharmaceutical drugs that are used in the treatment of cancer. This antibody drug conjugates are used to kill the tumor cells while protecting the healthy cells in the body. According to reports, there are 56 pharmaceutical companies developing antibody drug conjugates in 2019. By the technology advancement in the medical field, the monoclonal antibodies are linked with the cytotoxic drugs to target the tumors. The increase in the aging population, prevalence of cancer, and an increase in the obese population are some of the factors that are causing growth to the market during the forecast period 2020-2025. Even though there are large number of pharmaceutical companies the success rate in antibody drug conjugates is very less and limited to very few companies, company with good development have a booming market during the forecast period 2020-2025.

Full Report Link @ https://www.industryarc.com/Report/15696/antibody-drug-conjugate-market.html

By Product - Segment Analysis

The Product segment of Antibody Drug Conjugate Market has Adcertis, Kadcyla and Others. The Kadcyla segment registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025 with a CAGR of 14.1%, owing to the increased number of breast cancers globally. Trastuzumab emtansine is also known as ado-trastuzumab emtansine, has a trade name Kadcyla is an antibody drug conjugate which is used in the treatment of the HER2-positive metastatic breast cancer in patients. Adcetris, the trade name of Brentuximab vedotin having an application in the treatment of the relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma, these applications are driving the antibody drug conjugate market in this segment during the forecast period 2020-2025.

Request for Sample of the Report @ https://www.industryarc.com/pdfdownload.php?id=15696
Report Price: $ 4500 (Single User License)

By Application - Segment Analysis

The Application segment of the Antibody Drug Conjugate Market has Blood cancer, Ovarian cancer, Lung cancer, Skin cancer, Breast cancer, Brain tumor and Others. The Blood cancer segment which is sub-divided into Leukemia, Lymphoma, Multiple myeloma, registers for the highest market share in 2019 and is set to continue for the forecast period 2020-2025, owing to the increased number of people suffering from different types of cancers. The breast and lung cancer segments are also set to have the fastest growth during the forecast period 2020-2025. According to WHO reports of 2018, it is set to be that out of 6 death in the world one is owing to cancer. The lung and breast cancers are top in the global cancer effected patients with about 2.09 million people per each cancer type. The availability of antibodies like Kadcyla is driving the growth of the market for breast cancers segment during the forecast period 2020-2025.

By Geography - Segment Analysis

Based on Geography the global Antibody Drug Conjugate Market is segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America had a dominant share in terms of revenue in 2019 and it holds the largest market share of 41.3% during the forecast period 2020-2025, owing to the availability of the large number of key players in this region. Owing to growing population and rising in different types of cancers are boosting the growth of antibody drug conjugates in the Asia-pacific region. The rising awareness among the people, increased health care infrastructure and an increase in funding the government and private sector are driving the market in different regions globally during the forecast period 2020-2025.

Drivers – Antibody Drug Conjugate Market

High prevalence of cancer

The increase in diseases like blood cancers, lung cancer, breast cancer and other types of cancers are driving the growth of the antibody drug conjugate market during the forecast period 2020-2025.

Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=15696

Challenges – Antibody Drug Conjugate Market

High cost of procedures

The cost involved in the manufacturing and clinical trials of the antibody drug conjugate is hampering the growth of the market. The lack of funds and having less success rate in making of the antibody conjugates are challenging the market growth during the forecast period 2020-2025.

Antibody Drug Conjugate Industry outlook:

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Antibody Drug Conjugate Market. Key companies of this market are Genentech, ImmunoGen, Inc., Seattle Genetics, Concortis Biotherapeutics, Immunomedics, Pfizer Inc., Bayer HealthCare, Synthon, Agensys, Inc, Celldex Therapeutics and Others.

Acquisitions/Product Launches:

In June 2019, Seattle Genetics, Inc. has got FDA approval for the Polivy (Polatuzumab vedotin-piiq), a antibody drug conjugate, which is used in adults for the treatment of B-cell lymphoma.

In January 2019, Immunomedics Inc., has collaborated with the AstraZeneca for the study on combination of Imfinzi against PD-L1, whereas the Imfinzi is a human monoclonal antibody. And this study is to develop new antibody drug conjugate for breast cancer.

Key Takeaways

Geographically, North America’s Antibody Drug Conjugate Market accounted for the highest revenue share in 2019 and it is poised to dominate during the forecast period 2020-2025 owing to increased number of patients having different types of cancers.

The increase prevalence of cancers and an increase in need for best drug instead of chemotherapy is driving the manufacturers to develop new antibody conjugates for the better treatment of cancer.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Antibody Drug Conjugate Market report.

The increase in partnership and collaboration between different research centers and pharmaceuticals, increase in advance drug discovery are driving the growth of the antibody drug conjugate market.

Related Reports :

A. Antibody Drugs Market
https://www.industryarc.com/Report/15697/antibody-drugs-market.html

B. Antibiotics Drugs Market
https://www.industryarc.com/Report/15695/antibiotics-drugs-market.html

For more Lifesciences and Healthcare Market reports @ https://www.industryarc.com/Domain/8/lifesciences-healthcare-market-research.html

Venkat Reddy
Sales Director
Email: venkat@industryarc.com
Website: https://www.industryarc.com
Phone: (+1) 970-236-3677

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.

This release was published on openPR.